Drug
Daraxonrasib clinical trials
Also written RMC-6236.
Keep track of what changes. Save the daraxonrasib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2026 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
Revolution Medicines, Inc. (9) · Children's Oncology Group (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Synnovation Therapeutics, Inc. (1)
Often tested with
Tested in the same studies.
Zoldonrasib (3) · Gemcitabine (3) · Albumin-Bound Paclitaxel (3) · Paclitaxel (3) · Elironrasib (2) · PARP1 Inhibitor SNV1521 (1) · Pembrolizumab (1) · Cisplatin (1)
Studies
Open first, then newest update. How each study uses daraxonrasib is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingPhase 3Revolution Medicines, Inc.NCT07252232Written as daraxonrasib
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/2Revolution Medicines, Inc.NCT06162221Written as RMC-6236
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954Written as daraxonrasib
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07491445Written as daraxonrasib
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)RecruitingPhase 3Revolution Medicines, Inc.NCT06881784Written as daraxonrasib
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06445062Written as RMC-6236
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06128551Written as Daraxonrasib
- Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS MutationsNot yet recruitingPhase 1/2Children's Oncology GroupNCT07819838Written as Daraxonrasib
- Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNot yet recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07793253Written as Daraxonrasib
- First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic CancerNot yet recruitingPhase 1Synnovation Therapeutics, Inc.NCT07756281Written as daraxonrasib
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingPhase 1/2Revolution Medicines, Inc.NCT05379985Written as RMC-6236
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Active, not recruitingPhase 3Revolution Medicines, Inc.NCT06625320Written as RMC-6236
Given in every arm · 6 — daraxonrasib is usual care beside what is tested
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsRecruitingPhase 1/2Tango Therapeutics, Inc.NCT06922591Written as RMC-6236
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingPhase 2Bristol-Myers SquibbNCT07492680Written as Daraxonrasib
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsRecruitingPhase 1Revolution Medicines, Inc.NCT07349537Written as daraxonrasib
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT07397338Written as Daraxonrasib
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingPhase 1Revolution Medicines, Inc.NCT06040541Written as RMC-6236
- A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)Active, not recruitingPhase 1AmgenNCT06360354Written as RMC-6236
Codes
What other systems call daraxonrasib · ClinicalTrials.gg INT002100
- MeSH (NLM) C000731071daraxonrasibOne source NLM
- UNII (FDA) B6T47Y2UAPDARAXONRASIBConfirmed FDA, NLM, Wikidata
- Wikidata Q136659312daraxonrasibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C188048DaraxonrasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731071 | daraxonrasib | One source NLM |
| UNII (FDA) | B6T47Y2UAP | DARAXONRASIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q136659312 | daraxonrasib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C188048 | Daraxonrasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.